Prior Authorization Request (Urology Medication/Procedure)

Document Title: Prior Authorization Request – [Medication or Procedure Name] (Urology)

Request Type: [Initial / Continuation / Dose Change / Appeal Support]

Urgency: [Standard / Expedited] (If expedited, include one sentence clinical justification.)

Patient: [Name, DOB, Member ID]

Payer/Plan: [Payer name, plan type]

Requesting Clinician: [Name, credentials, NPI, practice name, phone/fax]

Requested Therapy: [For medication: drug name, strength, dose, frequency, quantity, days supply, duration. For procedure: procedure name, CPT/HCPCS, planned date range, site of service, laterality/device if relevant]

(If a required element is missing from the record, explicitly state as unknown, not available, or pending with plan to obtain. Do not fabricate details.)

Medical Necessity Summary

• [Primary diagnosis and ICD-10 code]
• [Severity and key symptoms with quantification] (Include validated scores or diary metrics when available.)
• [Why therapy is needed now and risk of delay]
• [Summary of failed or contraindicated alternatives] (Distinguish inefficacy vs intolerance.)
• [Expected benefit, measurable endpoints, and safety/monitoring approach]

Diagnosis and Clinical Context

• Primary diagnosis: [Diagnosis] – [ICD-10 code]
• Onset and course: [Approximate onset date and trajectory: stable / progressive / intermittent]
• Relevant comorbidities: [Conditions affecting therapy choice or urgency] (Include cardiovascular, cognitive, renal, hepatic, bleeding risk, fertility goals as applicable.)
• Differential diagnoses: [Diagnoses considered and excluded with method] (Include only if explicitly documented.)
• Pending confirmation: [Test ordered, scheduled date, risk of treatment delay] (Include only if applicable.)

Symptom Severity and Objective Findings

• Quantified symptom burden: [Symptom metrics with dates] (For OAB: urgency episodes/day, incontinence episodes/day, nocturia, pad use. For BPH/LUTS: IPSS/AUA-SI total and QoL item. For testosterone deficiency: relevant symptom inventory.)
• Objective measures: [PVR, Qmax, prostate volume/anatomy, serum labs with dates, UA/culture results, imaging findings] (Include only measures relevant to the requested therapy.)
• Functional impact: [Work/sleep impairment, safety risks, quality of life limitations]
• Clinical risk of non-treatment: [Retention, recurrent UTIs, bladder stones, hematuria, renal risk, other complications] (Include if applicable.)

(If metrics are unavailable, state unknown and whether data collection is in progress.)

Prior Treatments and Step Therapy History

(List all relevant pharmacologic and non-pharmacologic treatments. Clearly distinguish inefficacy vs intolerance. If exact dates/doses are unknown, state this and note if pharmacy records are being requested.)

Therapy	Dose/Schedule	Dates	Duration	Response	Adverse Effects	Reason Discontinued
[Therapy name and formulation]	[Dose and schedule]	[Start – Stop]	[Duration]	[Quantified response]	[Adverse effects]	[Inefficacy / Intolerance / Contraindicated / Other]

(Add rows as needed for each prior therapy.)

• Non-pharmacologic measures: [Behavioral/bladder training, pelvic floor therapy, fluid/caffeine modifications, timed voiding] (Include duration, dates, and quantified response.)
• Procedural history: [Prior urologic procedures relevant to current request with dates, outcomes, complications] (Include if applicable.)

Contraindications and Rationale for Not Using Preferred Alternatives

• Specific contraindications: [Disease-based, drug interactions, organ dysfunction, cognitive concerns, retention risk, fertility goals]
• Prior adverse reactions: [Agent, reaction, severity, timing, management, outcome]
• Clinical judgment rationale: [Patient-specific factors making theoretically possible alternatives inappropriate] (Explicitly label as clinical judgment.)

Requested Therapy Details

• Medication: [Drug name, formulation, dose, route, frequency, quantity, days supply, start date, planned duration, titration plan, concomitant therapies] (Include if requesting medication.)
• Procedure: [Procedure name, CPT/HCPCS code, anesthesia type, setting, planned date range, laterality, device/implant details] (Include if requesting procedure.)

Medical Necessity Narrative

[One concise paragraph linking diagnosis and documented severity to the requested therapy, explaining why alternatives are inadequate based on documented failures or contraindications, expected clinical benefit with measurable endpoints, safety justification and risk mitigation approach, and patient preferences when relevant among guideline-supported options.] (Use objective language referencing documented data without repeating all details.)

Goals and Monitoring Plan

• Reassessment timeframe: [Timeframe for response evaluation]
• Target improvements: [Measurable endpoints appropriate to condition]
• Baseline data obtained: [Key baselines relevant to monitoring]
• Safety monitoring: [Parameters, timing, and frequency] (Include BP, PVR, labs such as hematocrit/PSA/testosterone as applicable to therapy.)
• Stop/hold criteria: [Thresholds for adverse effects, lab abnormalities, or lack of efficacy triggering reassessment]
• Follow-up schedule: [Visit cadence and monitoring responsibility]
• Pending baseline tests: [Tests ordered and whether therapy can safely start while awaiting results] (Include if applicable.)

Additional Condition-Specific Documentation

(Include only the section relevant to the current request.)

• For OAB requests: [Bladder diary metrics, behavioral therapy duration and response, antimuscarinic trial details before beta-3 agonist, anticholinergic burden concerns, retention risk assessment, BP monitoring plan if applicable; for third-line therapies include counseling on retention risk and self-catheterization ability]
• For BPH procedure requests: [IPSS/QoL scores, prostate volume and median lobe status, Qmax/PVR, BPH complications strengthening necessity, medical therapy trials, procedure selection rationale addressing anatomy/size/bleeding risk/sexual function priorities/durability]
• For testosterone requests: [Two AM testosterone measurements with dates/times, symptom inventory, fertility goals explicitly stated, baseline hematocrit and PSA, etiology workup if indicated, monitoring schedule with stop criteria]
• For continuation/renewal: [Baseline vs current metrics showing response, adherence and refill history, adverse effects and management, relapse risk if stopped, why alternatives remain inappropriate]

Supporting Documentation Attached

• [Relevant clinic notes with dates]
• [Symptom diaries or validated questionnaires with dates]
• [Laboratory results with dates]
• [Imaging or procedure reports with dates]
• [Medication fill history or pharmacy records]
• [Prior denial letter and response mapping] (Include if resubmission or appeal.)

Attestation and Signature

I attest that the information provided is accurate, medically necessary, and drawn from the patient's medical record.

Clinician Signature: ____________________________ Date: [Date]

Printed Name/Credentials: [Name, credentials] | NPI: [NPI]

Contact for Peer-to-Peer: [Phone], [Fax]